Financiere des Professionnels Fonds d investissement inc. Makes New $527,000 Investment in Halozyme Therapeutics, Inc. $HALO

Key Points

• Financiere des Professionnels Fonds d'investissement inc. has acquired a new stake of 10,130 shares in Halozyme Therapeutics, valued at approximately $527,000.
• Insider transactions revealed that CEO Helen Torley sold 20,000 shares for about $1.49 million, resulting in a 2.65% decrease in her position.
• Halozyme Therapeutics recently posted a strong earnings report with revenue of $325.72 million, surpassing analyst estimates and achieving a 40.8% increase compared to the previous year.

Financiere des Professionnels Fonds d investissement inc. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 10,130 shares of the biopharmaceutical company's stock, valued at approximately $527,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. MRA Advisory Group bought a new stake in Halozyme Therapeutics in the second quarter valued at approximately $454,000. Strs Ohio bought a new stake in Halozyme Therapeutics in the first quarter valued at approximately $1,914,000. Acadian Asset Management LLC bought a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $195,000. Intech Investment Management LLC raised its holdings in shares of Halozyme Therapeutics by 9.9% during the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company's stock valued at $9,776,000 after acquiring an additional 13,789 shares in the last quarter. Finally, Focus Partners Wealth raised its holdings in shares of Halozyme Therapeutics by 57.8% during the first quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company's stock valued at $7,709,000 after acquiring an additional 44,260 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

HALO traded up $1.13 on Friday, hitting $77.81. 6,252,281 shares of the company's stock traded hands, compared to its average volume of 1,750,342. The company's 50 day simple moving average is $67.13 and its 200-day simple moving average is $61.09. The firm has a market cap of $9.10 billion, a price-to-earnings ratio of 17.81, a P/E/G ratio of 0.43 and a beta of 1.19. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $77.95. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The company had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the company earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 4,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total transaction of $294,720.00. Following the sale, the director owned 46,952 shares of the company's stock, valued at approximately $3,459,423.36. This trade represents a 7.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Nicole Labrosse sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the sale, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. This trade represents a 45.14% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 104,000 shares of company stock valued at $6,771,120. 2.40% of the stock is owned by company insiders.

Analyst Ratings Changes

HALO has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th. Morgan Stanley increased their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. JMP Securities increased their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Hold" and an average price target of $67.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.